ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.
|Videos|September 20, 2016
CBTF Programs and Research
Author(s)Children's Brain Tumor Foundation
Children's Brain Tumor Foundation explains the importance of their research and programs.
Advertisement
Why is it so important to support CBTF's research and programs? Watch this video featuring families, survivors, and some of our greatest supporters to find out why.
Advertisement
Related to this article
Long-term QUILT-3.032 data in BCG-unresponsive NMIBC with CIS show durable responses for some patients and a long, surveillance-heavy course.
The approval in stage II/III MSI-H/dMMR rectal cancer rests on AZUR-1, in which 71% of patients needed no treatment beyond dostarlimab.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
Eppie Bass, APRN, explains how nurses can counsel patients on flu-like symptoms vs warning signs with nogapendekin alfa inbakicept-pmln and BCG.
Discover how equine-assisted services support patients with cancer by improving emotional wellness, building confidence, and enhancing quality of life.
Two Winship nurses explain how to talk with breast cancer survivors about GLP-1 receptor agonists, from endocrine therapy to access barriers.
A Moffitt nurse practitioner explains rollout, handling, triage, and patient education for nogapendekin alfa inbakicept-pmln plus BCG.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer
2
How AI Could Ease the Cost Crisis in Cancer Care
3
Anktiva Plus BCG: 84% of Responders Cystectomy-Free at 3 Years
4
Automated Breast Ultrasound Tied to Fewer False-Positives in Dense Breasts
5